Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind Randomized Extension Study to Assess the Long-term Efficacy and Safety of Linzagolix in Subjects With Endometriosis-associated Pain

NCT04335591 is registered in ClinicalTrials.gov with Kissei Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT04335591
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04335591 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind Randomized Extension Study to Assess the Long-term Efficacy and Safety of Linzagolix in Subjects With Endometriosis-associated Pain
Lead sponsor
Kissei Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
March 5, 2020
Completion date
December 15, 2022
Enrollment
356 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

endometriosis